Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case study
- 129 Downloads
The proportion of people surviving pancreatic cancer is extremely low, with just 10% of patients diagnosed with any stage of the disease living beyond 1 year and a 5-year relative survival rate of <5%. The lack of effective therapy is one the main reason for such a bleak outlook. Herein, we report on a patient with pancreatic adenocarcinoma and metastatic disease treated with a combination regimen of gemcitabine and lenalidomide, without major complications. We also present in vitro data that highlight a hyper-additive effect of the two drugs when used in combination. To date, 33 months after diagnosis, the patient remains well and continues in full-time employment.
KeywordsPancreatic cancer Drug combination therapy Gemcitabine Lenalidomide
- 2.Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for pancreatic cancer across the world. HPB (Oxford). 2008;10:58–62.Google Scholar
- 3.Office National Statistics: http://www.statistics.gov.uk/StatBase/xsdataset.asp?vlnk=982&Pos=&ColRank=1&Rank=544. Accessed 23 Oct 2008.
- 7.Bartlett JB, Michael A, Clarke IA, Dredge K, Nicholson S, Kristeleit H, et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer. 2004;90:955–61. doi: 10.1038/sj.bjc.6601579.CrossRefPubMedGoogle Scholar